Rhythm Pharmaceuticals (RYTM) Stock: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$93.41
-1.81 (-1.90%)
▼
5d:
-4.98%
30d:
-10.82%
90d:
-18.18%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RYTM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RYTM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $93.41, which is considered oversold relative to its 30-day fair value range of $96.79 to $107.51.
Technical Outlook: Technically, RYTM is in a uptrend. The price is currently testing key support at $93.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $138.59 (+48.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RYTM is in a uptrend. The price is currently testing key support at $93.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $138.59 (+48.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$96.79 -
$107.51
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
Protect Your Profits
Holding RYTM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.4% below Wall St target ($138.59)
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$96.79 -
$107.51
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$6.14
(6.6%)
Support & Resistance Levels
Support Level
$93.00
Resistance Level
$101.85
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-152.48
Wall Street Target
$138.59
(+48.4%)
Revenue Growth (YoY)
46.9%
Profit Margin
-85.6%
Share & Embed Analysis
Last updated: October 02, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 74 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 52 HOLD |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
